Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/2538
Title: | Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial | Authors: | Van Vlierberghe, H Leroux-Roels, G Adler, M. Bourgeois, N Horsmans, Y Brouwer, J Colle, I Delwaide, J Brenard, R Bastens, B. Henrion, J de Vries, RA de Galocsy, C Michielsen, P Nevens, Y. ROBAEYS, Geert BRUCKERS, Liesbeth |
Issue Date: | 2003 | Publisher: | BLACKWELL PUBLISHING LTD | Source: | JOURNAL OF VIRAL HEPATITIS, 10(6). p. 460-466 | Abstract: | The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66% vs 47'%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53% vs 50%). 41%, vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment. end of treatment response and sustained responses did not differ. | Notes: | State Univ Ghent Hosp, Dept Gastroenterol & Hepatol, B-9000 Ghent, Belgium. State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium. ULB Erasme, Dept Gastroenterol, Brussels, Belgium. KULeuven, Dept Hepatol, Louvain, Belgium. UCL, Dept Gastroenterol, Brussels, Belgium. Erasmus Univ, Hosp Dijkzigt, Dept Gastroenterol, NL-3015 GD Rotterdam, Netherlands. CHU Sart Tilman, Dept Gastroenterol, B-4000 Liege, Belgium. Clin St Joseph, Dept Gastroenterol, Liege, Belgium. Hop Jolimont, Dept Gastroenterol, Haine St Paul, Belgium. Rijnstate Hosp, Dept Gastroenterol, Arnhem, Netherlands. Clin St Anne St Remi St Etienne, Dept Gastroenterol, Brussels, Belgium. UZA, Dept Gastroenterol, Antwerp, Belgium. Acad Hosp St Jan, Dept Gastroenterol, Genk, Belgium. LUC Diepenbeek, Ctr Stat, Diepenbeek, Belgium.Van Vlierberghe, H, State Univ Ghent Hosp, Dept Gastroenterol & Hepatol, Pintelaan 185, B-9000 Ghent, Belgium. | Keywords: | hepatitis C virus; induction; interferon alpha 2b; ribavirin; treatment | Document URI: | http://hdl.handle.net/1942/2538 | ISSN: | 1352-0504 | e-ISSN: | 1365-2893 | DOI: | 10.1046/j.1365-2893.2003.00466.x | ISI #: | 000186323500010 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2004 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
14
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
14
checked on Oct 12, 2024
Page view(s)
102
checked on Jun 28, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.